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Summary
To evaluate the role of oncogenic RAS mutations in pancreatic tumorigenesis, we directed endogenous expression of
KRASG12D to progenitor cells of the mouse pancreas. We find that physiological levels of KrasG12D induce ductal lesions that
recapitulate the full spectrum of human pancreatic intraepithelial neoplasias (PanINs), putative precursors to invasive
pancreatic cancer. The PanINs are highly proliferative, show evidence of histological progression, and activate signaling
pathways normally quiescent in ductal epithelium, suggesting potential therapeutic and chemopreventive targets for
the cognate human condition. At low frequency, these lesions also progress spontaneously to invasive and metastatic
adenocarcinomas, establishing PanINs as definitive precursors to the invasive disease. Finally, mice with PanINs have an
identifiable serum proteomic signature, suggesting a means of detecting the preinvasive state in patients.
Introduction del Castillo, 1992). The essential incurability of this disease is
reflected in virtually identical annual incidence and mortality
Infiltrating ductal adenocarcinoma of the pancreas (PDA) ac- figures, projected to number 30,300 and 29,700 cases, respec-
counts for over 95% of all exocrine pancreatic malignancies tively, for 2003 (Jemal et al., 2003). The median survival for
and is the fifth-leading cause of cancer-related deaths in the patients with PDA is 4–6 months, in part because the disease
United States. Infiltrating PDA is almost uniformly fatal, with a usually only becomes clinically apparent at late stages, and
because it resists all forms of conventional chemotherapy andfive-year survival of less than 5% (Warshaw and Fernandez-
S I G N I F I C A N C E
It is axiomatic in clinical oncology that early detection of cancers increases the likelihood of cure. This is particularly true for
pancreatic ductal adenocarcinoma, in which complete resection at even the earliest stage of invasive disease results in dismal
long-term prognosis. Understanding the pathogenesis of the preinvasive lesions, termed pancreatic intraepithelial neoplasias (PanINs),
and developing the means to detect them, therefore represent urgent needs. We have generated a mouse model of PanIN and
find that the lesions progress histologically, culminating in fully invasive and metastatic disease. Moreover, we demonstrate a highly
reliable means of detecting PanINs in the serum proteome of mutant animals. These results illustrate the potential of genetically
engineered mice to accurately model the earliest stages of human neoplasias.
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Figure 1. Targeting endogenous KRASG12D expression to the mouse pancreas
A: Simplified schematic diagram of the program of transcription factor expression in the developing mouse pancreas. PDX-1 expression (blue) is apparent
by embryonic day 8.5 (E8.5), while P48 expression (red) begins on approximately E9.5. The resultant PDX-1 and P48 double-positive cells give rise to all of
the cells of the mature organ.
B: Conditional LSL-KRASG12D allele and generation of expressed KRASG12D allele after Cre-mediated excision-recombination. Arrows indicate relative position
of PCR primers used to detect alleles. PCR distinguishes presence of recombined allele from WT allele by addition of 40 bp (34 bp for LoxP site plus 6 bp
added SalI restriction site). A separate reaction is used to detect the presence of the unrecombined conditional allele (not shown).
C: PCR of tail (T) and pancreatic (P) DNA from 2- and 5-month-old control, PDX-1-Cre; LSL-KRASG12D and P48/Cre; LSL-KRASG12D mice. The recombined allele
is present in the pancreata but not the tails of compound mutant mice.
D: Pancreata from young (2 months, top panels) and older (5 months, bottom panels) PDX-1-Cre;LSL-KRASG12D and P48/Cre;LSL-KRASG12D animals are larger
than those of the respective control animals. Arrows indicate pancreatic nodules.
E: KrasG12D, Ras-GTP, and total Ras levels in whole pancreatic lysates of 2-month-old PDX-1-Cre;LSL-KRASG12D, P48/Cre;LSL-KRASG12D, and control animals.
Detectable levels of KrasG12D and Ras-GTP are seen in compound mutant animals but not in controls.
radiotherapy. Several factors conspire to obscure the diagnosis to complete surgical resection, long-term survival is exceedingly
rare. The vast majority of even highly selected patients, pos-of early pancreatic ductal cancer, including the retroperitoneal
location of the pancreas and the small size of most of the sessing small primary lesions (less than 2 cm), disease-free
resection margins, and negative lymph nodes, inevitably suc-precursor lesions, which renders them below the detection
threshold of current imaging modalities. Even when serendipi- cumb to recurrent or metastatic disease (Allison et al., 1998;
Yeo et al., 2002a). Thus, unlike other epithelial malignancies, ittously discovered at its earliest stages, and therefore amenable
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appears that from its very inception, PDA is already a micro- (Kawaguchi et al., 2002) and into endocrine cells that migrate to
the spleen (Krapp et al., 1998). P48/ animals lack a discerniblemetastatic disease. Understanding the pathogenesis of the pre-
invasive state, and developing effective strategies to detect pancreas and succumb shortly after birth. The PDX-1 and P48
double-positive progenitor cells give rise to all the mature cellspreinvasive pancreatic neoplasms, are therefore of paramount
importance. of the pancreas (Figure 1A). In the adult mouse, PDX-1 expres-
sion is essentially confined to the islet cells, while P48 is re-Similar to long-established models for other epithelial malig-
nancies, such as breast, colon, and prostate, a progression stricted to acinar cells.
To target expression of oncogenic KRAS to pancreatic pro-model for the precursor lesions of PDA has been elaborated
(Cubilla and Fitzgerald, 1975, 1976; Hruban et al., 2000a; Klims- genitor cells, a conditionally expressed allele was first con-
structed as previously described (Jackson et al., 2001) (Figuretra and Longnecker, 1994). These lesions, recently codified un-
der the collective term pancreatic intraepithelial neoplasia 1B). The targeting vector contains genetic elements that inhibit
transcription and translation flanked by functional LoxP sites.(PanIN), are grouped into three histologic stages based on in-
creasing degrees of architectural and nuclear atypia (Kern et This Lox-STOP-Lox (LSL) construct was inserted into the mouse
genomic KRAS locus upstream of a modified exon 1 engineeredal., 2001). A genetic progression model is also emerging which
serves to substantiate and illuminate the histological description to contain a G→ A transition in codon 12. This mutation, com-
monly found in human PDA, results in a glycine to aspartic acid(Hruban et al., 2000b). Activating mutations in the KRAS proto-
oncogene are found in over 90% of invasive PDA and are substitution in the expressed protein, compromising both its
intrinsic and extrinsic GTPase activities and resulting in constitu-thought to represent an initiating event. Genetic and epigenetic
inactivations of a number of tumor suppressor genes, including tive downstream signaling of Ras effector pathways. Expression
of the mutated allele is achieved by interbreeding LSL-KRASG12Dp16INK4a, p53, DPC4 and BRCA2, increase in frequency in pro-
gressively higher PanIN stages, and culminate in incidences of mice with animals that express Cre recombinase from the pan-
creatic-specific promoters, PDX-1 or P48. Lineage tracing stud-approximately 90%, 50%–70%, 55%, and 10%, respectively,
in invasive PDA. A few heritable predispositions to the disease ies demonstrate a stochastic pattern of Cre expression in the
pancreas of the transgenically derived PDX-1-Cre animals, whilehave been described, involving kindreds with germline muta-
tions in the tumor suppressor genes p16INK4a, BRCA2, LKB1, the knockin strategy used to generate the P48/Cre strain (Kawa-
guchi et al., 2002) results in uniform expression throughout theand MLH1 (Jaffee et al., 2002). Interestingly, the median age at
presentation in these kindreds is not significantly different from organ (Supplemental Figure S1 at http://www.cancercell.org/
cgi/content/full/4/6/437/DC1). Prior to breeding with Cre-sporadic cases, suggesting that these mutations identify genes
involved in the progression, and not initiation, of a multigenic expressing animals, LSL-KRASG12D mice are functionally hetero-
zygous for the wild-type allele (KRAS/). Excision of the si-process.
A number of tumor suppressor gene knockout and onco- lencing cassette and subsequent recombination allows for
expression of the mutant allele, resulting in a heterozygousgene transgenic mouse models have been developed in recent
years incorporating strategies informed by the genetic studies mutant condition (KRAS/G12D). The excision-recombination
event leaves behind a single LoxP site, evidence of which cancited above; to date, however, none have recapitulated the
features of invasive human PDA or of its noninvasive precursor be demonstrated by PCR (Figure 1C). Note that only DNA iso-
lated from the pancreata of these mice, and not from the tails,state. We hypothesized that physiological levels of oncogenic
KRAS would serve to initiate pancreatic cancer. We report here reveals evidence of recombination.
The pancreata from compound mutant mice are larger thanthat endogenous expression of KRASG12D in progenitor cells of
the mouse pancreas induces the entire progression of pancre- their littermate controls and, particularly in older mice, often
have focally nodular parenchyma (Figure 1D). Consistent withatic ductal adenocarcinoma from preinvasive neoplasias to inva-
sive and metastatic disease. Furthermore, mice with preinvasive expression of the KRASG12D allele, total protein lysates from the
pancreata of compound mutant mice contain mutant proteindisease have a diagnostic serum proteomic profile that could
serve as the basis for detecting the cognate human condition. and reveal increased levels of activated, or GTP-bound, Ras
(Figure 1E). The slightly higher levels of KrasG12D and Ras-GTP
in P48/Cre;LSL-KRASG12D pancreatic lysates are consistent withResults
expression of the mutant allele throughout the organ. These
studies do not, of course, identify the specific cellular compart-Targeting expression of KRASG12D
to the mouse pancreas ment(s) within the pancreas that express the KRASG12D allele.
Nevertheless, they do establish that the conditional KRASG12DThe ability to target gene expression to different compartments
of the mouse pancreas has been aided greatly by recent ad- allele is efficiently recombined in the pancreata of PDX-1-
vances in our understanding of the developmental program of Cre;LSL-KRASG12D and P48/Cre;LSL-KRASG12D compound mu-
this vital organ. These studies have identified several transcrip- tant mice, resulting in expression of the oncogenic protein and
tion factors critical to cellular fate decisions in the developing elevated Ras-GTP levels.
pancreas (reviewed in Kim and MacDonald, 2002) (Figure 1A).
The first identifiable pancreatic progenitor cells arise in the dor- Endogenous KRASG12D expression induces pancreatic
intraepithelial neoplasias (PanINs)sal and ventral endoderm at embryonic day 8 in the fetal mouse.
Expression of PDX-1/IPF1 occurs around E8.5, and its homozy- The pancreata of compound mutant mice developed ductal
lesions with complete penetrance (33 of 33 animals) that weregous deletion is an embryonic lethal event (Offield et al., 1996).
P48/PTF1 is expressed slightly later and is required to commit identical to all three stages of human PanINs. Representative
examples of the types of lesions seen in these animals arecells to a pancreatic fate; when it is absent, cells of the develop-
ing pancreatic bud instead differentiate into duodenal epithelium shown (Figure 2). The normal pancreas is characterized by an
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Figure 2. Endogenous KRASG12D expression induces both early- (top panels) and advanced- (bottom panels) stage pancreatic intraepithelial neoplasias
(PanINs)
A: Wild-type pancreas revealing normal cuboidal ductal epithelium in cross-section (arrowhead), islet (is), and surrounding acinar tissue (400).
B: Reactive duct (arrow) showing enlarged nuclei and normal duct (arrowhead) in adjacent lobule (400).
C: PanIN-1A in small intralobular duct (arrow) and adjacent normal interlobular duct (delimited by arrowheads). Note the relative sizes of the two ductal
structures (200).
D: PanIN-1A (arrow) and adjacent normal duct (arrowhead) and islet (is) (400).
E: PanIN-1B (arrow) showing papillary architecture and an adjacent PanIN-1A (arrowhead) (400).
F: Papillary architecture of PanIN-1B lesion at abrupt transition from more normal appearing ductal epithelium (arrowheads) (1000).
G and H: Higher-grade PanIN-2 lesions (arrows) reveal more significant loss of polarity and moderate nuclear atypia. In (G), an adjacent lesion within the
same duct has features more consistent with PanIN-1B (arrowhead, 400).
I–L: High-grade PanIN-3 lesions reveal complete loss of cellular polarity, significant nuclear atypia, and budding of cell clusters into the ductal lumen. Goblet
cells (arrows) are also seen with increasing frequency, as is the surrounding fibroinflammatory reaction (asterisk) (1000).
abundance of acinar tissue with scattered islets and rarely-seen (Figure 2B). PanIN-1A lesions are characterized by a transition
from the normal cuboidal morphology to a columnar phenotypeducts (Figure 2A). Normal ductal epithelium is comprised of
cuboidal cells with uniform round nuclei. Occasionally, so-called with abundant supranuclear, mucin-containing cytoplasm (Fig-
ures 2C and 2D). The polarity of these cells is still maintainedreactive ducts, which are thought to reflect injured epithelium,
are seen. These ducts are characterized by slightly larger nuclei with basally located nuclei, and nuclear atypia, when seen at
all, is minimal. Such lesions were observed in compound mutantwith less condensed chromatin, but only minimally increased
cytoplasm, and are not thought to represent preinvasive lesions mice as young as two weeks old. We note that the development
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of these lesions was restricted to the small, intralobular ducts specification of this region of the developing foregut endoderm
(Kawaguchi et al., 2002). The relative infrequency of such eventsof the pancreas, just as in the human condition; the larger inter-
lobular ducts appeared unaffected (Figure 2C). The develop- is also reflected in the lack of detectable recombination of the
LSL-KRASG12D allele in the duodena of most P48/Cre;LSLG12Dment of papillary or micropapillary ductal lesions without sig-
nificant loss of polarity or nuclear atypia identifies them as animals (Supplemental Figure S2F).
PanIN-1B (Figures 2E and 2F). Importantly, the pancreata of
affected animals retained their overall organotypic architecture Characterization of PanINs
The proliferative index of PanINs was assessed by expressionwith abundant normal-appearing acini and islets.
As the mice aged, higher-grade PanINs were observed with of PCNA. In wild-type animals, the basal level of PCNA expres-
sion was low, measuring 0.55  0.05% in ducts, 0.94  0.14%increasing frequency. Moderate nuclear atypia and a loss of
polarity, manifested by movement away from a strictly basal in acini, and 0% in islets. By comparison, in PDX-1-Cre;LSL-
KRASG12D and P48/Cre;LSL-KRASG12D animals, 16% 1.8% andlocation of nuclei, herald the transition to PanIN-2 lesions (Fig-
ures 2G and 2H). In PanIN-3 lesions, significant nuclear atypia 22%  3.0%, respectively, of ductal cells in PanINs expressed
PCNA (Figure 3A). The proliferative index of acinar cells in com-and complete loss of polarity are observed, such that it is often
not possible within the center of one of these lesions to discern pound mutant animals was also increased, though to a much
lesser degree than PanINs: 3.0 0.6% of acinar cells in PDX-1-luminal from basal boundaries (Figures 2I–2L). Goblet cells, mu-
cus-producing cells normally restricted to respiratory and intes- Cre;LSL-KRASG12D mice were PCNA-positive, while 6.7  0.8%
PCNA-positive acinar cells were observed in P48/Cre;LSL-tinal epithelia, were seen in PanINs of various stages, but most
frequently in PanIN-3 lesions. Though not part of the formal KRASG12D animals. Neither the normal ductal cells nor islet cells
in either cohort of compound mutant animals showed any in-diagnostic criteria for PanINs, they are an associated hallmark
of human PanINs and are consistent with the notion of an undif- crease in PCNA expression (Figure 3B). Importantly, pancreata
from compound mutant animals did not express detectableferentiated or inappropriately differentiated pancreatic ductal
epithelium toward a more intestinal phenotype. In the PanIN-3 levels of p21CIP/WAF, a cell cycle inhibitor and p53 target gene
(Figure 3C), arguing against the possibility that the decreasedlesions shown here, nuclear enlargement and pleomorphism
are apparent; in addition, clusters of cells can be seen which proliferative rates of acinar and islet cells compared with PanINs
were due to Ras-induced senescence in the former cell com-appear to have “budded off” into the lumen. These represent
cardinal features of human PanIN-3 lesions, also referred to as partments (Serrano et al., 1997).
The epithelial nature of the observed PanINs was confirmedcarcinoma-in-situ.
In many of the older mice, the pancreata contained extensive by intense expression of cytokeratin-19 (CK-19), an epithelial
cell marker (Figures 3D). Consistent with human PanINs, andductal lesions, and the acinar parenchyma was largely replaced
by an intense stromal, or desmoplastic, reaction comprised of with their presumptive status as precursors of adenocarcino-
mas, an abundant mucin content of PanINs in compound mutantinflammatory cells, fibroblasts, and collagen deposition (Figures
2I–2K). This fibroinflammatory reaction is highly reminiscent of animals was demonstrated by intense Alcian blue staining (Fig-
ure 3E) and by immunoreactivity to the mucin-specific protein,that seen in human pancreatic cancers and may be secondary to
luminal obstruction from the intraductal proliferations. A similar Muc5 (Figure 3F). Finally, we note that PanINs expressed only
low levels of PDX-1, which can nevertheless be discerned whenspectrum of ductal lesions was seen with both PDX-1-Cre;LSL-
KRASG12D and P48/Cre;LSL-KRASG12D mice. We conclude, there- compared to the lack of expression in surrounding acini (Figures
2G and 2H) and to normal ducts in control animals (Figurefore, that the targeted recombination of a conditional KRASG12D
allele in pancreatic progenitor cells induces the full spectrum 2I). Moderate expression of PDX-1 was observed in duodenal
crypts, again consistent with the observation of allelic recombi-of pancreatic intraepithelial neoplasias, and substantiates the
KRASG12D mutation as an initiating event in pancreatic cancer. nation in the small bowel noted earlier, while high levels of
PDX-1 expression were restricted to the endocrine cells of bothPDX-1-Cre;LSL-KRASG12D animals did occasionally develop
additional tumors with varying penetrance (Supplemental Table control and compound mutant adult animals, as expected (Fig-
ures 3G–3I).S1), including mucocutaneous papillomas (not shown), intestinal
metaplasia of the gastric epithelium (Supplemental Figures S2A
and S2B), and hyperplastic polyps of the duodenum (Supple- PanINs show evidence of histologic progression
To determine more rigorously if the PanINs progress histologi-mental Figures S2C and S2D). The occurrence of these lesions
of the gastrointestinal epithelium likely reflects the expression cally, the total number of ductal lesions and their grade were
scored in representative pancreatic sections of cohorts of PDX-of PDX-1 in foregut endothelium progenitor cells during develop-
ment (Offield et al., 1996). Consistent with this expression pat- 1-Cre;LSL-KRASG12D mice of varying age (Figure 4). To decrease
the likelihood of scoring the same potentially serpentine ducttern, recombination of the conditional allele was detected in the
stomach and small bowel, in addition to the pancreas, of PDX- more than once, only the highest-grade lesion per pancreatic
lobule was evaluated. Reactive ducts were not counted as true1-Cre;LSL-KRASG12D mice, as well as in cutaneous papillomas
but not normal adjacent skin (Supplemental Figure S2E). With PanINs. Only lesions that satisfied the accepted criteria for
PanIN grades 1–3 were scored as such. It should be noted thatone exception, full necropsies of P48/Cre;LSL-KRASG12D animals
did not reveal extrapancreatic pathology (Supplemental Table a fair degree of variability exists in total tumor burden among
mice of the same age, even among littermates. This variabilityS2). One animal displayed evidence of duodenal hyperplasia
(not shown), perhaps a result of haploinsufficiency of P48 in may reflect the inherently unpredictable nature of transgenic
expression of the Cre enzyme in PDX-1-Cre mice. This caveatP48/Cre mice. In lineage-tracing studies in P48/lacZ mice, rare
P48-expressing cells were retained in the duodenum, the pre- notwithstanding, several points were readily apparent. Both the
total number of PanINs and their grade clearly increased withsumed result of insufficient levels of p48 to secure the pancreatic
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Figure 3. Characterization of PanINs
A: High levels of PCNA expression (arrows) seen in numerous PanINs of a PDX-1-Cre;LSL-KRASG12D mouse but not in surrounding acinar tissue (400).
B: Absence of PCNA expression in normal pancreatic ducts (arrowheads) from the same compound mutant animal as in (A) (400).
C: Absence of p21 immunoreactivity in a normal duct (arrowhead), acini, and islet (is) of a PDX-1-Cre;LSL-KRASG12D mouse (400).
D: Intense expression of epithelial cell marker, cytokeratin-19 (CK-19), in numerous PanINs (examples indicated by arrows) of a compound mutant animal
(400).
E: Alcian blue stain reveals abundant mucin content of a PanIN-1A (arrow) which is absent from islets (is), acini (ac), and an adjacent reactive duct
(arrowhead) (400).
F: Immunoreactivity to mucin-specific protein, Muc5, is seen in PanINs (arrows), but not in adjacent acini (ac) (400).
G–I: Immunohistochemical detection of PDX-1 expression in pancreata from PDX-1-Cre; LSL-KRASG12D (G and H) and control mice (I). G: Intense nuclear
PDX-1 expression is seen in islets (arrowhead), high-level expression in intestinal crypts (open arrowheads), and faint expression in Pan-INs (arrows, 200).
H: Higher-power view of G (400). I: High-level expression in islets (is) but not in ducts (arrowhead) (400).
advancing age of the mice (Figure 4). In animals 5 months of age PanINs activate normally quiescent pathways
We next sought to examine these lesions with specific regardor less, the vast majority of ducts were normal. When observed,
to pathways that offer potential therapeutic and/or chemoprev-ductal lesions were largely PanIN-1A. Specifically, at 2.25
entive targets. The Notch signaling pathway is involved in de-months, 80% of ducts were normal; this percentage de-
termining cellular fate in the embryonic development of a varietycreased to 68% at 4–5 months (p .089, using Poisson regres-
of tissues (Artavanis-Tsakonas et al., 1999), as well as in thesion). By 7–10 months, however, more neoplastic (82% of total)
pathological state associated with Alzheimer’s disease (Fortini,than normal ducts were observed (p 1 108 compared with
2002). Although apparently necessary for the early development2 months, p 1.5 104 compared with 4.5 months). Although
of the pancreas, Notch signaling is normally suppressed in thethe neoplastic ducts still largely consisted of low-grade (1A and
adult organ (Apelqvist et al., 1999; Jensen et al., 2000). Very
1B) lesions (65%), a substantial number of grade 2 lesions (16%)
recently, this pathway has been identified as inappropriately
and the first PanIN-3 lesions could now be seen. Relative to upregulated in human pancreatic cancer specimens (Miyamoto
the total number of ducts, the incidence of high-grade (2 and et al., 2003). Activation of this pathway can be assessed by
3) PanINs in the oldest cohort was significantly increased when nuclear expression of one of its downstream target genes, the
compared with both young (p  7  105) and intermediate- transcription factor Hes1. PanIN lesions demonstrated strong
aged mice (p  4  104), largely because high-grade lesions nuclear expression and faint cytoplasmic expression of Hes1
were rarely if ever observed in mice younger than 5 months. (Figure 5A). Nuclear expression was not seen in the normal
Similar overall findings were noted in cohorts of P48/Cre;LSL- ducts or islet cells of compound mutant animals, or in these
compartments in control animals (Figure 5B); expression in rareKRASG12D mice.
442 CANCER CELL : DECEMBER 2003
A R T I C L E
nohistochemical labeling for Cox-2 was observed in the cyto-
plasm of PanINs, but not in the ductal cells of control animals
(Figures 5C and 5D). Acini and islets revealed varying, but sub-
stantially decreased, levels of COX2 expression.
Finally, we investigated the expression of matrix metallopro-
teinase-7 (MMP-7), a member of the family of zinc-dependent
extracellular proteases (Brinckerhoff and Matrisian, 2002). Ho-
mozygous deletion of MMP-7 has been shown to inhibit tumori-
genesis (Wilson et al., 1997), while transgenic overexpression
can promote it (Rudolph-Owen et al., 1998). Inappropriate
MMP-7 expression has also been identified in preinvasive and
invasive human pancreatic cancer specimens (Crawford et al.,
2002). We found focally elevated expression of MMP-7 in a
subset of PanIN lesions, but not in the normal ducts or other
cells of the pancreas (Figures 5E and 5F), similar to the pattern
of expression seen in human specimens. Interestingly, and again
as noted in human pancreata, MMP-7 expression did not appear
to correlate with PanIN grade.
Progression to invasive and metastatic
Figure 4. Histologic progression of PanINs in PDX-1-Cre;LSL-KRASG12D mice ductal adenocarcinoma
Percentages ( SEM) of normal (nl) and neoplastic ducts by grade (1A, 1B, In a cohort of animals (n  29) being followed longitudinally
2, 3) in mice of average age 2.25 months (n  6), 4.5 months (n  4), and for evidence of disease progression, two mice, one PDX-1-
9 months (n  4). p values: *,  1  108; **,  1.5  104; ,  7  105;
Cre;LSL-KRASG12D (aged 6.25 months) and one P48/Cre;LSL-,  4  104.
KRASG12D (aged 8.25 months), have thus far developed and
succumbed to invasive and metastatic pancreatic ductal adeno-
carcioma. Both mice developed locally invasive disease and
metastases to the liver. The PDX-1-Cre;LSL-KRASG12D animalcentroacinar cells was occasionally seen (not shown) as has
developed additional sites of metastatic disease and will bebeen described previously (Miyamoto et al., 2003).
described in greater detail.PanINs also expressed increased levels of cyclooxygenase
At necropsy, a profuse hemorrhagic ascites was noted. The2, a component of the prostaglandin pathway involved in the
pancreas was large, firm, and fibrotic, and appeared to be en-inflammatory response. Elevated COX2 expression has been
casing the small bowel (Figure 6A). Nodular densities were ob-described in both human PanINs (Maitra et al., 2002) and inva-
sive PDA (Maitra et al., 2002; Tucker et al., 1999). Intense immu- served on the liver, diaphragm, and pleural surfaces. Histologic
Figure 5. Signaling pathways in PanINs
A and B: Nuclear expression of Hes1 (arrows) is seen in PanINs (A, arrows) but not in normal ducts (B, arrowheads) (1000).
C and D: Cytoplasmic expression of COX-2 is high in PanINs (C, arrows), markedly lower in surrounding acini, and absent in control ducts (D, arrowhead)
(400).
E and F: Focal expression of MMP-7 is found in PanINs (E, arrows). No MMP-7 expression was observed in the ductal epithelium (F, arrowheads) or other
structures of control animals (400).
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Figure 6. Invasive (top panels) and metastatic (bottom panels) pancreatic ductal adenocarcinoma (PDA) in PDX-1-Cre; LSL-KRASG12D mouse
A: Gross photograph of abdominal organs. Arrow indicates dramatically enlarged and nodular pancreas seen encasing the small bowel. Note the multiple
smaller (open arrowheads) and single large (closed arrowhead) liver metastases.
B: PanINs (boxes) at the junction between normal acini above and invasive PDA below (100).
C and D: Higher magnifications of PanINs at the border of invasive cancer (400).
E and F: Well-differentiated regions of invasive PDA revealing prominent glandular architecture (400).
G: Region of poorly differentiated PDA within same tumor (400).
H: CK-19 expression in well-differentiated region of PDA (400).
I–K: Several distinct liver metastases are indicated (I [dotted lines, 40] and J [asterisk, 200]). K: serial section of J demonstrating immunoreactivity to
the epithelial marker CK-19 in metastasis but not adjacent normal hepatic parenchyma (200).
L: Lung metastasis (arrow, 200).
M and N: Pleural nodules (M) (arrows, 100) showing immunoreactivity to CK-19 (N) (400 of boxed region).
O: Peripancreatic lymph node metastasis (asterisk, 200).
P: Diaphragmatic invasion by tumor cells (asterisk) in finger-like projections (200).
Q: Neural plexus (np) and associated nerve fibers (arrows) invaded by PDA. The nerve fibers are encased by tumor cells (asterisks, 400).
assessment of the pancreas revealed a diffusely infiltrative ade- (Figure 6H). These more well-differentiated regions of the tumor
also reacted with Alcian blue and with mucicarmine, a mucin-nocarcinoma with scattered low and high grade PanINs (Figures
6B–6D). A predominantly glandular pattern of differentiation was specific stain, establishing their designation as a glandular mu-
cin-producing carcinoma, or adenocarcinoma (not shown).noted (Figures 6E and 6F), although there were significant areas
of more poorly differentiated carcinoma as well (Figure 6G). The liver contained numerous scattered metastatic lesions
which clearly revealed glandular differentiation (Figures 6I andThe regions manifesting glandular differentiation, in particular,
expressed high levels of CK-19, confirming their epithelial nature 6J) and which also were CK-19-positive (Figure 6K). A similar
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Table 1. Serum proteomic analysis of murine PanIN: Pilot study
# serum # Training # Test
Cohort Age (months) # mice samples Failed QA/QC samples samples Sensitivity Specificity
PanIN 9.4  0.3 12 48 2 25 21 90.5% 97.7%
(95% CI (95% CI of
Control 9.0  0.2 25 100 17 40 43 of 68.3– 87.7–
98.8%) 99.9%)
histologic appearance and epithelial character was demon- confirmed PanIN, but no evidence of invasive or metastatic
disease. Twenty-five age-matched littermate controls (a mix ofstrated by metastases to the lung parenchyma (Figure 6L) and
pleural surfaces (Figures 6M and 6N). Several identified peripan- wild-type, PDX-1-Cre, and P48/Cre mice) were similarly bled
and sacrificed, and were confirmed to have normal pancreatacreatic lymph nodes had been infiltrated by tumor cells (Figure
6O), and finger-like projections of tumor cells had invaded into without histologic evidence of PanIN. A total of 25 PanIN serum
samples and 40 samples from littermate controls were sub-the diaphragm (Figure 6P). A metastatic lesion to the adrenal
cortex was also noted (not shown). jected to SELDI-TOF mass spectrometry to generate an un-
blinded training set for our bioinformatics algorithm. The resul-The presence of neural and vascular invasion in human pan-
creatic ductal cancer portends an especially poor prognosis, tant model was highly predictive, with a sensitivity of 90.5%
(95% CI of 68.3–98.8%) and a specificity of 97.7% (95% CI ofand invasion of nervous plexi is a major source of patient mor-
bidity, resulting in severe and often intractable pain. Invasion 87.7%–99.9%). These results suggested, in principle, that the
serum proteome of compound mutant mice with preinvasiveof a nervous plexus and encasement of the nerve fibers by
tumor cells was observed in this animal as well (Figure 6Q). pancreatic ductal disease is distinguishable from that of healthy
littermate controls.Cancer cells can be seen completely encasing the nerve fibers
and infiltrating the plexus of neuronal cell bodies. Not surpris- Having established the potential feasibility of detecting pre-
invasive pancreatic disease in this small study, we next endeav-ingly, vascular invasion manifested by infiltration of a vein was
also noted (not shown). The sites of metastases observed in ored to perform a prospective study on a larger set of serially
collected samples and subject them to higher resolution massthis animal are precisely those found in human pancreatic ductal
adenocarcinoma and further underscore the accuracy of this spectrometry. For these analyses, we used a younger cohort
of animals of average age 5.5 0.25 months. The use of youngermouse model in recapitulating the path to the human disease.
mice increases the stringency of the test in several ways. First,
these animals have a lower total burden of PanINs and a shiftIdentification of a proteomic signature
in mice with PanIN toward earlier stage lesions (see Figure 4). Compound mutant
mice at this age have a vast majority of normal (67%) as com-Serum proteomic analysis has recently been shown to be an
effective means to detect early or recurrent malignancy in pa- pared with diseased ducts (33%). Second, and as a direct con-
sequence, such animals are much less likely to have developedtients with ovarian (Petricoin et al., 2002b), breast (Li et al.,
2002), and prostate cancer (Adam et al., 2002; Petricoin et al., invasive ductal cancer. Third, and perhaps most importantly,
they have substantially less chronic injury and fibrosis than the2002a). These studies coupled a high-throughput mass spectro-
metric method, surfaced enhanced laser desorption ionization older cohort. It is formally possible that the signature identified
in the initial pilot study represented the presence of pancreatictime-of-flight (SELDI-TOF), with pattern recognition algorithms
to detect significant differences that exist between patients and fibrosis and not PanIN. Thus, we used this cohort of animals
to determine if it was possible to detect very early preinvasivehealthy subjects in the low molecular weight range (less than
20,000 MW) of the serum proteome. We wondered whether the disease and to do so in the relative absence of the underlying
fibrosis that accompanies the greater PanIN burden found inserum from PanIN-afflicted animals contained an identifiable
proteomic profile that distinguished diseased from normal ani- older animals.
Independent, serial serum collections were performed on amals. We note that unfractionated serum was used for these
analyses, as it has recently been shown that retention of albumin cohort of 39 compound mutant animals of average age 5.5 
0.25 months and 40 aged-matched littermate controls to gener-is essential to the diagnostic power of sera from ovarian and
prostate cancer patients, presumably because albumin avidly ate a total of 80 PanIN and 111 control serum samples. All
animals were followed for a minimum of three additional weeksbinds the low MW proteins and concentrates them over time
by preventing their otherwise inevitable renal excretion (Liotta after the final serum collection without manifesting overt signs of
illness, further decreasing the likelihood that they had developedet al., 2003).
In a small pilot study designed to establish proof-of-princi- invasive disease. Training on a subset of 46 PanIN samples and
51 control samples generated a model comprised of 10 specificple, we used a cohort of mice of average age 9.0  0.2 months,
which would be expected to have a very high burden of PanINs: molecular ions whose vectorially combined relative intensities
were able to accurately distinguish samples from the two popu-based on our previous analyses of histologic progression (Figure
4), we would expect the vast majority (80%) of the ducts to lations (Table 2). When tested on a separate blinded set of 34
PanIN samples and 60 controls, the model was able to distin-contain PanIN lesions. We performed terminal bleeds on a co-
hort (n  12) of PDX-1-Cre;LSL-KRASG12D and P48/Cre;LSL- guish cases and controls in this relatively young cohort of mice
with a sensitivity of 90% (95% CI of 82.5%–99.9%) and a speci-KRASG12D animals and prepared multiple serum samples from
each animal (Table 1). Each animal had extensive, histologically ficity of 87% (95% CI of 81.6%–99.9%). In addition, we note
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Table 2. Serum proteomic analysis of murine PanIN: Prospective study
A: Parameters of sample populations
Average age # serum Failed # Training # Test
Cohort (months) # mice samples QA/QC samples samples Sensitivity Specificity
PanIN 5.5  0.25 39 95 15 46 34 90% 87%
(95% CI (95% CI of
Control 6.5  0.2 40 125 14 51 60 of 82.5– 81.6–
99.9%) 99.9%)












that samples from PDX-1-Cre;LSL-KRASG12D and P48/Cre;LSL- pitulates some important genetic features of human pancreatic
cancer; however, this progression does not occur through histo-KRASG12D mice were detected with equal fidelity, suggesting
that the identified proteomic signature was most likely related logically defined PanIN lesions, and the relationship of this
model to human pancreatic carcinogenesis remains unclearto the presence of PanIN and not to the minor extrapancreatic
pathology in these animals, which differs between the two co- (Wagner et al., 2001). We have demonstrated here that targeted
endogenous expression of an oncogenic KRAS allele in thehorts. Thus, these results demonstrate that it is possible to
detect even very early preinvasive disease in the serum pro- mouse pancreas initiates the development of PanINs identical
to all three stages found in the cognate human condition. Atteome.
low frequency, mice with PanIN spontaneously develop both
locally invasive adenocarcinoma and metastatic disease, withDiscussion
sites of spread exactly as found in human pancreatic cancer,
underscoring both the relevance of this model and establishingThe generation of an animal model that incorporates the genetic
PanINs as bona fide precursors to pancreatic ductal adenocarci-events and faithfully recapitulates the cardinal features of inva-
noma.sive pancreatic ductal adenocarcinoma, or of the precursor le-
Transgenic animal models differ from those targeting endog-sions collectively termed pancreatic intraepithelial neoplasias
enous gene expression in several important ways. First, the(PanINs), has remained elusive to date. Targeted disruption of
random nature of transgene insertion into the host genomea number of tumor suppressor genes believed to be important
results in unpredictable positional effects on levels of expres-in human pancreatic oncogenesis, including p53 (Donehower
sion. Second, in constructs driven by heterologous promoters,et al., 1992; Jacks et al., 1994), p16INK4a (Serrano et al., 1996),
the normal physiological regulation of gene expression gov-DPC4 (Sirard et al., 1998), and BRCA2 (Suzuki et al., 1997), has
erned by the endogenous promoter is lost. The cellular effectsnot yielded any form of pancreatic pathology. The development
of oncogenic RAS have been shown to be exquisitely dependentof oncogenic mutations thought to act as initiating events may
upon both the levels and context of RAS expression in a numbertherefore represent the rate-limiting step. Two interesting and
of experimental systems (reviewed in Shields et al., 2000). In adistinct transgenic mouse models, each expressing a KRAS
variety of cell types, ectopic overexpression of RAS inducesoncogene from a different heterologous pancreatic-specific pro-
cell cycle arrest and senescence in the absence of cooperatingmoter, were recently described (Brembeck et al., 2003; Grippo
tumor suppressor or oncogenic mutations (Land et al., 1983;et al., 2003). Although these mice did exhibit varying degrees
Ruley, 1983; Serrano et al., 1997). Conversely, endogenousand types of pancreatic pathology, they too failed to recapitulate
expression of KRASG12D in mouse embryo fibroblasts (MEFs)the signature features of PDA or of PanIN. We, too, have pre-
stimulates proliferation and induces focus formation in cultureviously engineered a mouse to overexpress KRASG12D from the
without evidence of additional karyotypic events (D.A.T. et al.,acinar cell-specific MIST-1 promoter. These mice exhibit wide-
submitted). Moreover, targeted expression of this allele in thespread acinar metaplasia and develop a mixed exocrine pancre-
mouse lung causes hyperproliferative lesions that progress fromatic cancer with cystic, acinar, and ductal features (D.A.T., N.
adenomas to adenocarcinomas (Jackson et al., 2001). TheseWillis, C. Pin, S. Konieczny, J. Glickman, and T.J., unpublished
findings are consistent with the presumptive role of activatingdata). Finally, transgenic overexpression of TGF	 in acinar cells
RAS mutations as initiating events in a number of malignancies.also results in acinar-to-ductal metaplasia (Sandgren et al.,
During the preparation of this manuscript, the description1990; Wagner et al., 1998). When placed in a p53-deficient
background, these mice develop an invasive disease that reca- of a model involving conditional endogenous expression of an-
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other oncogenic KRAS allele (KRASG12V ) was reported. This of Cre behind the P48 promoter means that, in principle, every
cell of the adult pancreas in compound mutant mice has poten-model employed a bicistronic allele (KRASG12V-IRES-
-geo) created
by targeting a fused IRES-
-geo cassette to the 3 untranslated tially rearranged the oncogenic KRAS allele to permit expres-
sion. Nevertheless, we see the slowly progressive acquisitionregion of a mutated KRAS locus (Guerra et al., 2003). Interest-
ingly, when bred with transgenic CMV-Cre animals, expression of ductal lesions similar to that seen in the transgenic, and hence
stochastic, PDX-1-Cre-associated model. It may be that acinar-of activated KRAS from this modified allele failed to induce
pancreatic lesions or gastric epithelial hyperplasias in mice even to-ductal transdifferentiation is a relatively slow process that
requires weeks to months in vivo after the activation of onco-up to 8 months of age, despite demonstrated translation of the
bicistronic transcript by X-gal staining. Low-grade pancreatic genic KRAS expression. However, at least in explants of devel-
oping pancreatic buds transfected in vitro with Notch, the ob-lesions, described by the authors as ductal metaplasia, were
seen only in the context of an additional mutation in a cyclin- served transdifferentiation of acinar-like cells occurred within
3–4 days (Miyamoto et al., 2003).dependent kinase, CDK4R24C (Cdk4R24C has a markedly de-
creased binding affinity for p16INK4a and thereby resists its tumor We favor an alternate scheme for the development of PanINs
seen here. Pancreatic stem cells periodically undergo either cellsuppressor affects). On the other hand, the transgenic ectopic
expression of KRASG12V from an epithelial-specific CK-19 pro- division to replenish themselves or enter into a differentiation
pathway to replace an end-stage cell. We propose that themoter induces the formation of gastric mucous neck cell hyper-
plasias, and some pancreatic ductal hyperplasias, but fails to periodic diversion of a progenitor cell that expresses the re-
arranged KRASG12D allele toward differentiation along a ductalrecapitulate the true spectrum of PanINs (Brembeck et al., 2003).
Together with the findings reported here, these studies confirm pathway provides the basis for the evolution of a PanIN. Differ-
entiation along acinar or islet cell pathways does not providethat both the levels of RAS expression and the cellular context
conspire to determine biological outcome. It may be that the the proper context for KRASG12D to induce true PanINs. Cellular
injury, such as that which accompanies ductal obstruction andbiological consequences of KRASG12V and KRASG12D oncogenes
are distinct or, alternatively, that strain-specific effects are re- associated acute and chronic pancreatitis, stimulates increased
entry of progenitor cells into the differentiation pathway andsponsible for some of the differences discussed here. However,
it is also possible that the unusual configuration of the bicistronic increased numbers of PanINs, which in turn cause further ob-
struction and injury. This scenario is consistent with the in-allele affects the expression and/or terminal splicing of the KRAS
transcript, thereby decreasing the overall levels of oncogenic creased associated risk of developing pancreatic cancer in
patients with chronic pancreatitis (Lowenfels et al., 1993). Exper-RAS, or changing the relative ratio of the alternatively spliced
KRAS-4A and KRAS-4B transcripts. Indeed, it has been shown iments are currently underway to formally address whether ma-
ture or progenitor cell compartments of the pancreas give risethat introduction into the mouse genome of a bicistronic con-
struct, directing expression from a single promoter of genes to PanINs by breeding LSL-KRASG12D mice to mice that express
Cre recombinase from the Elastase or Cytokeratin-19 promot-separated by an IRES, results in markedly decreased expression
levels of both transcripts compared with separate constructs ers, active in mature acinar and ductal cells, respectively.
The findings of activated Notch signaling, as manifested bydriven by independent promoters (Jankowsky et al., 2001).
In our system, excision of the silencing cassette upstream Hes1 expression, and increased expression of COX-2 and
MMP-7 in PanINs each provide a basis for therapeutic and/orof an introduced KRASG12D mutation can occur in pancreatic
progenitor cells early in development, and in the islet cells (for chemoprevention strategies. Agents that interfere with each of
these activities are already in approved or investigational usePDX-1-Cre crosses) or acinar cells (for P48-Cre crosses) of the
adult mouse. Thus, the model accounts for the possibility that in the clinic. For example, inhibitors of -secretase, one of the
required proteases in transducing Notch receptor signaling, arethe initiation of tumorigenesis occurs in tissue stem cell com-
partments while not precluding the study of such events in currently in clinical trials for Alzheimer’s disease (Josien, 2002).
The use of nonsteroidal anti-inflammatory drugs has been asso-differentiated cells (Reya et al., 2001). As noted above, an alter-
nate theory of the genesis of ductal adenocarcinoma in the ciated with a decreased incidence in pancreatic cancer (Ander-
son et al., 2002), which together with the increased expressionpancreas involves the metaplastic transdifferentiation of acinar
to ductal cells. The robust expression of Hes1 and low, but of Cox-2 observed here in ductal lesions suggests that Cox-2
activity may represent an important part of the program of eventsdetectable, levels of PDX-1 expression in the PanINs described
here are consistent with the notion of a relatively undifferentiated initiated by oncogenic KRAS. Finally, matrix metalloproteinases
have traditionally been thought to be important for late stagesor inappropriately differentiated population of cells; of course,
such cells could result from progenitor cells gone awry, or from of tumorigenesis involving invasion and metastasis and, accord-
ingly, MMP inhibitors have been used in a number of trialsthe dedifferentiation of mature ductal or acinar cells. While we
cannot formally exclude the possibility that transdifferentiation encompassing a variety of metastatic malignancies (Coussens
et al., 2002). Unfortunately, these trials were largely unsuccess-of acinar to ductal cells occurs in our model system, several
points would at least seem to argue against it being the preferred ful. Given the expression of MMP-7 in early-stage PanINs, it
may be that these agents would be more efficacious in earlierroute to PanINs. First, the overall PanIN burden and progression,
cellular histology, activated signaling pathways, and serum pro- stages of disease or as chemopreventive agents.
There are currently no non-invasive tests with sufficient sen-teomic signatures found in PDX-1-Cre;LSL-KRASG12D and
P48/Cre;LSL-KRASG12D compound mutant mice are highly con- sitivity and specificity to detect pancreatic cancer early enough
to effect cures (Hingorani and Tuveson, 2003; Rosty and Gog-gruous despite different modes of transmission of the Cre allele
and consequent expression in adult pancreatic cells. Thus, we gins, 2002). The most commonly used biomarker of invasive
pancreatic cancer, CA (carbohydrate antigen) 19-9, is usefulsee essentially normal acinar and islet compartments, respec-
tively, in each of these model systems. In addition, the knockin only for following disease progression or response to therapy
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(Yeo et al., 2002b). Indeed, in a recent prospective study of man PanIN in the mouse that faithfully recapitulates the cardinal
features of this precursor state to invasive pancreatic cancer.patients with clinically suspected pancreatic malignancy but
without a radiographically evident mass, the sensitivity and The presence of PanINs can be detected accurately in the serum
proteome of mutant mice. The fidelity of the model is affirmed byspecificity of CA 19-9 to detect the invasive cancer were only
67% and 88%, respectively (Urgell et al., 2000). The very notion the spontaneous development of fully invasive and metastatic
ductal adenocarcinomas. Thus, the model provides a uniqueof early detection requires reassessment for pancreatic cancer,
however, as even resection of stage I invasive disease affords platform to study mechanisms of disease pathogenesis, to de-
velop detection and therapeutic strategies for preinvasive dis-negligible 10-year survival (Allison et al., 1998). In the absence
of therapies that kill metastatic pancreatic cancer cells, which ease in high-risk patient populations, and to systematically eval-
uate multigenic models of invasive and metastatic pancreaticapparently arise from the inception of malignant transformation,
the only hope for cures lies in the detection and eradication of cancer.
the preinvasive state. It is, of course, currently impossible to
Experimental proceduresdevelop a serologic test for PanIN in patients because of the
conundrum of being unable to distinguish those that harbor the
Mouse strains
lesions from those who do not. The risks and difficulties of The conditional LSL-KRASG12D mice (Jackson et al., 2001) and P48/Cre mice
pancreatic needle biopsy preclude its routine use to establish (Kawaguchi et al., 2002) were previously described. PDX-1-Cre transgenic
a histologic diagnosis. We have shown here in an animal model mice were generated by injecting fertilized FVB/N oocytes with the PDX-1-
Cre transgene, and founder mice were identified that expressed Cre in aof PanIN that a defining serum proteomic signature exists. Re-
mosaic pattern in the pancreas, as assessed in the background of a r26markably, this signature was detectable even in mice with very
Cre reporter.early-stage preinvasive lesions and low overall burden of dis-
ease. Further analyses of the key molecular ions identified in
KRASG12D allele recombination and Ras-GTP assays
the mass spectra may reveal proteins that could form the basis The recombined KRASG12D allele was identified by PCR as previously de-
of specific serologic assays. In principle, it may even be possible scribed (Jackson et al., 2001). Ras-GTP was precipitated with Raf-GST
to use the proteomic patterns derived from this mouse model and detected by immunoblotting per the manufacturer’s instructions (UBI).
KrasG12D protein was detected by specific antiserum (Johnson et al., 2001).to identify similar patterns in patients with PanIN.
Finally, we believe that this model of PanIN represents a
Histology and immunohistochemistrysuitable platform upon which to build more accurate models of
Paraffin embedded murine tissues were processed by standard methods.invasive pancreatic adenocarcinoma. In addition to impeding Details for immunohistochemistry are provided in the Supplemental Data at
the development of diagnostic tests as noted above, the inability http://www.cancercell.org/cgi/content/full/4/6/437/DC1.
to routinely sample pancreatic tissue has also hampered the
elaboration of histologic and genetic progression models for Statistical analyses
Statistical analyses were carried out using Splus version 6.0 and Stata 8.0.human PDA. Thus, it has not been possible to directly chronicle
See the Supplemental Data for details.the evolution of ductal pancreatic cancer with serial biopsies,
as has been done with colorectal cancer, for example (Fearon
Serum proteomicsand Vogelstein, 1990). A large body of evidence, accumulated
Serum preparation, mass spectroscopy, and pattern recognition data analy-
over several decades from resected and autopsy specimens, ses were performed as previously described (Petricoin et al., 2002b). Further
has led to a very useful conceptual model of preinvasive disease details are supplied in the Supplemental Data.
involving progression through discrete stages. Though compel-
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